Results from First-in-Human Phase I Study of a Novel CD19-1XX Chimeric Antigen Receptor with Calibrated Signaling in Large B-Cell Lymphoma

0
343
In this first-in-human, Phase I, dose escalation and expansion clinical trial, patients with relapsed or refractory large B-cell lymphoma received 19(T2)28z-1XX CAR T cells at four dose levels.
[Journal of Clinical Oncology]
Abstract